The market has been down on Karyopharm Therapeutics Inc (KPTI) stock recently. KPTI gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.
Karyopharm Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on KPTI!
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With KPTI Stock Today?
Karyopharm Therapeutics Inc (KPTI) stock is flat 0.36% while the S&P 500 is up 0.62% as of 11:42 AM on Thursday, Mar 21. KPTI is unchanged $0.00 from the previous closing price of $1.40 on volume of 222,125 shares. Over the past year the S&P 500 has risen 31.33% while KPTI is down -59.48%. KPTI lost -$1.25 per share in the over the last 12 months.
More About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's lead compound, XPOVIO(R) (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade(R) (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Click Here to get the full Stock Report for Karyopharm Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
